Effects of Ido1 on mouse decidualization

被引:0
|
作者
D.-D. Li
Y.-H. Yin
J.-Y. Wu
Z.-Q. Yang
H. Cao
Q.-L. Zhang
B. Guo
Z.-P. Yue
机构
[1] Jilin University,College of Veterinary Medicine
[2] Guizhou Minzu University,Department of Laboratory Medicine
[3] General Hospital of Jinan Military Region of PLA,undefined
来源
Molecular Biology | 2015年 / 49卷
关键词
Ido1; decidualization; uterus; mouse;
D O I
暂无
中图分类号
学科分类号
摘要
Indoleamine 2,3-dioxygenase 1 (Ido1) is a rate-limiting enzyme which converts the essential amino acid tryptophan to kynurenine. The aim of this study was to investigate the expression and regulation of Ido1 in mouse uterus during decidualization. The results showed that Ido1 mRNA expression gradually increased from day 1 to 4 of pregnancy and reached the peak level on day 4. On days 5–8 of pregnancy, a low level of Ido1 expression was observed in the uteri. Simultaneously, Ido1 mRNA was also lowly expressed in the decidualized uterus and the stromal cells treated with 8-Br-cAMP. Under in vitro decidualization, the expression of Ido1 mRNA gradually declined. Further studies found that overexpression of Ido1 can inhibit the expression of decidualization marker genes PRL, IGFBP1 and Dtprp under in vitro decidualization while inhibition of Ido1 with L-1-MT can induce the expression of these marker genes. Ido1 can prevent uterine stromal cells proliferation and enhance the expression of the Bax gene and increase the Bax/Bcl2 ratio under in vitro decidualization. Additionally, Ido1 can also modulate the expression of the MMP2 gene. In the uterine stromal cells, estrogen and progesterone can stimulate the expression of Ido1. These data indicate that Ido1 may play an important role during mouse decidualization and may be regulated by estrogen and progesterone in the uterine stromal cells.
引用
收藏
页码:581 / 588
页数:7
相关论文
共 50 条
  • [1] Effects of Ido1 on mouse decidualization
    Li, D. -D.
    Yin, Y. -H.
    Wu, J. -Y.
    Yang, Z. -Q.
    Cao, H.
    Zhang, Q. -L.
    Guo, B.
    Yue, Z. -P.
    MOLECULAR BIOLOGY, 2015, 49 (04) : 581 - 588
  • [2] IDO1 AND TARGETED IMMUNOTHERAPY IN A MOUSE GLIOBLASTOMA MODEL
    Ladomersky, Erik
    Zhai, Lijie
    Gritsina, Galina
    Lauing, Kristen
    Genet, Matthew
    Bloch, Orin
    James, C. David
    Wainwright, Derek
    NEURO-ONCOLOGY, 2016, 18 : 94 - 94
  • [3] Amyloid β neurotoxicity is IDO1–Kyn–AhR dependent and blocked by IDO1 inhibitor
    Zhenzhen Duan
    Shengnan Zhang
    Heng Liang
    Zikang Xing
    Leilei Guo
    Lei Shi
    Lisha Du
    Chunxiang Kuang
    Osamu Takikawa
    Qing Yang
    Signal Transduction and Targeted Therapy, 5
  • [4] IDO1 INHIBITORS FOR CANCER IMMUNOTHERAPY
    Alford, B.
    Cox, K.
    Soliman, H.
    DRUGS OF THE FUTURE, 2016, 41 (09) : 553 - 559
  • [5] ADVANCED AGING INCREASES IMMUNOSUPPRESSIVE IDO1 LEVELS THAT ARE UNINHIBITED BY IDO1 ENZYME INHIBITOR TREATMENT IN MODELS OF GLIOBLASTOMA
    Ladomersky, Erik
    Zhai, Lijie
    Lauing, Kristen
    Qian, Jun
    Otto-Meyer, Sebastian
    Savoor, Rohan
    Wainwright, Derek
    NEURO-ONCOLOGY, 2019, 21 : 123 - 123
  • [6] Novel inhibitors of human IDO1 and TDO
    Banerjee, Monali
    Middya, Sandip
    Shrivastava, Ritesh
    Raina, Sushil
    Yadav, Dharmendra
    Singh, Satveer
    Manna, Anindita
    Chakraborty, Debjani
    Surya, Arjun
    CANCER IMMUNOLOGY RESEARCH, 2015, 3 (10)
  • [7] Deleterious role of IDO1 in cardiac repair
    Irene Fernández-Ruiz
    Nature Reviews Cardiology, 2021, 18 : 150 - 150
  • [8] IDO1 in cancer: a Gemini of immune checkpoints
    Zhai, Lijie
    Ladomersky, Erik
    Lenzen, Alicia
    Nguyen, Brenda
    Patel, Ricky
    Lauing, Kristen L.
    Wu, Meijing
    Wainwright, Derek A.
    CELLULAR & MOLECULAR IMMUNOLOGY, 2018, 15 (05) : 447 - 457
  • [9] IDO1 expression in glioma molecular subtypes
    Snyder, James
    Malta, Tathiane M.
    Noushmehr, Houtan
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] Alzheimer's and metabolism wed with IDO1
    Johnson, Lance A.
    Macauley, Shannon L.
    SCIENCE, 2024, 385 (6711) : 826 - 827